Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

US11401506B2 · kind B2 · utility

Assignees

• H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. · US
• Board nf Regents The Inivercitvof Texas Cvctom · US

Inventors

• Amod A. Sarnaik · Tampa, US
• Jeffrey S. Weber · Tampa, US
• Shari Pilon-Thomas · Tampa, US
• Laszlo Radvanyi · Acton, US
• Jessica Ann Chacon · Philadelphia, US
• James J. Mulé · Land O' Lakes, US
• MacLean S. Hall · Tampa, US

Key dates

• Filing date: Dec 20, 2018
• Grant date: Aug 2, 2022
• Expiry date: Dec 20, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2501/998
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.